Related Experiment Video
Updated: Aug 6, 2026
A Semi-Automated and Reproducible Biological-Based Method to Quantify Calcium Deposition In Vitro
Published on: June 2, 2022
Vascular calcification and renal osteodystrophy relationship in chronic kidney disease
1Indiana University School of Medicine and Roudebush Veterans Affairs Medical Center, Indianapolis, IN 46202, USA. smoe@iupui.edu
Insights
Patients with chronic kidney disease (CKD) face a dual threat from cardiovascular disease and abnormal bone health. These conditions significantly increase mortality risk, particularly in end-stage renal disease (ESRD) patients.
Area of Science:
- Nephrology
- Cardiology
- Bone Metabolism
Background:
- Cardiovascular disease (CVD) and stroke cause 60-70% of deaths in end-stage renal disease (ESRD) patients, a 10-20 fold increased risk compared to the general population.
- Chronic kidney disease (CKD) patients, including those on dialysis, exhibit higher rates of coronary artery calcification and cardiovascular mortality.
- Bone abnormalities, such as low bone mass and increased fracture incidence, are also prevalent in CKD and dialysis patients, with hip fractures nearly doubling mortality.
Purpose of the Study:
- To explore the link between abnormal bone metabolism and vascular calcification in CKD patients.
- To understand how CKD-related bone disorders exacerbate cardiovascular risk.
- To highlight the combined impact of vascular risk factors and bone abnormalities in CKD.
Main Methods:
- Review of existing cross-sectional studies examining the relationship between osteoporosis and coronary artery calcification.
- Analysis of in vitro and ex vivo evidence demonstrating vascular calcification as an active, cell-mediated process.
- Identification of CKD-specific mechanisms contributing to vascular calcification.
Main Results:
- A significant inverse relationship exists between osteoporosis and coronary artery calcification in both the general population and ESRD patients.
- Vascular calcification is an active process exacerbated by mineral metabolism disorders common in CKD.
- CKD contributes to vascular calcification through mechanisms like altered parathyroid hormone (PTH) secretion, hyperphosphatemia, hypercalcemia, and specific treatments.
Conclusions:
- The coexistence of vascular risk factors and abnormal bone metabolism in CKD patients presents a significant, "double threat" to patient well-being.
- Understanding and addressing bone abnormalities is crucial for managing cardiovascular risk in CKD.
- Targeting mineral metabolism disorders may mitigate vascular calcification and improve outcomes in CKD patients.
Abstract:
Cardiovascular disease and stroke account for 60-70% of all deaths in patients with end-stage renal disease (ESRD), at a risk that is 10-20-fold the age- and sex-matched general population. There is also increased coronary artery calcification and increased cardiovascular mortality in chronic kidney disease (CKD) and dialysis patients compared with the general population. Bone is similarly abnormal in CKD. There is an increased incidence of low bone mass and fractures in dialysis patients compared with the general population. Furthermore, a hip fracture in a dialysis patient is associated with a doubling of the mortality observed in nondialysis patients with a hip fracture. These two problems may be linked, as cross-sectional studies have demonstrated an inverse relationship between osteoporosis and coronary artery calcification in the general population and in ESRD patients. In vitro and ex vivo, there is clear evidence that vascular calcification is an active cell-mediated process, made worse by disorders of mineral metabolism. Many factors known to be associated with cardiovascular disease in CKD patients can directly increase calcification in vitro. In addition, in CKD, there are many mechanisms by which bone may adversely affect vascular calcification including disorders of bone remodelling, altered secretion of parathyroid hormone (PTH), hyperphosphatemia, hypercalcaemia, use of calcium based binders, and excessive vitamin D therapy. The coexistence of vascular risk factors and abnormal bone represent a double threat to the well being of patients with CKD.
Related Concept Videos
01:24Chronic Kidney Disease II: Clinical Manifestations
01:31Osteoclasts in Bone Remodeling
01:25Chronic Kidney Disease I: Introduction
01:21Skeleton and Calcium Homeostasis
01:29Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
01:25Role of Vitamins in Maintaining Bone Health
Vitamin A
Vitamin A is involved in the process of bone remodeling. Retinoic acid, the active metabolite of Vitamin A, has nuclear receptors in osteoblasts and osteoclasts, which are involved in bone remodeling.
Vitamin B12
Vitamin B12 acts as a cofactor during the formation of osteoblast-related proteins, such as osteocalcin. Vitamin B12 plays a role...